gilead help save world regeneron hold beer clear
neither compani utter word remdesivir posit updat earlier
week provid hope final scienc contribut physician tool box
therapeut option much requir bridg gap viabl vaccin
end think regn antibodi cocktail purpose-built program
like like societi best shot regard moreov human test begin
next month regn cocktail suspect next sever month see increas
focu approach data becom avail given highlight herein deep
dive program clinic premis commerci implic bottom line
much still unknown like chanc
bridg vaccin current vaccin program on-going project
success candid could avail month expert agre
time-frame unlik given lack herd immun second wave
outbreak expect near-term treatment approach need convalesc plasma
compel option signific limit manufactur sars-
antibodi promis altern address broad array need
like regeneron chanc recogn preciou littl
disclos regard program numer program right heel
like clinic next month also know use velocimmun
platform acceler develop express confid cover
vast major known mutat moreov program mani common
ebola antibodi cocktail therapi like approv year
sale possibl caveat unknown dose frequenc price
approv timelin etc tri answer question potenti data
time host firesid chat cso georg yancopoulo may
also updat model praluent restructur new account present
restructur praluent agreement effect book us
sale receiv ex-u royalti sanofi chang account
present collabor effect overhaul model account
chang net neutral ep adjust expens estim
ep estim come modestli along partial laps discount
period bring target
commerci regulatori clinic ip risk associ market pipelin product
regeneron develop market therapi address varieti diseas
back
debt total capit
piper sandler seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis report read conjunct import disclosur inform
includ attest regul analyst certif found page report follow site
page
there light
end tunnel
time prepar
new normal
gilead help save world regeneron hold beer clear neither
compani utter word remdesivir posit updat earli week provid
hope final scienc contribut physician tool box therapeut option
much requir bridg gap viabl vaccin end think regn sars-
antibodi cocktail purpose-built program like like societi best shot
regard moreov human test begin next month regn cocktail suspect
next sever month see increas focu approach data becom avail
given highlight herein deep dive program clinic premis
commerci implic bottom line much still unknown like chanc
posit impact us social distanc larg implement late march begin
manifest number new case level begun declin though
note vari geograph region mani state prepar method lift
shelter-in-plac restrict slowli start reopen economi howev despit wh
coronaviru task forc guidelin propos state region open includ
period decreas case number move three phase reopen stringent
relax measur hand state case count still rise lessen social
distanc measur georgia tennesse ohio us ideal expect
number state begin lift stay-at-hom restrict throughout may time-frame
though appear light end tunnel earli mitig strategi prove
effect substanti amount uncertainti remain contain futur outbreak
region epidem mani publish reopen guidelin highlight need
wide scale readili avail test mani governor continu voic
frustrat inabl secur test kit given continu shortag new infect
test combin unreli serolog test fals posit rate
lack contact trace would surpris see infect rate rebound late
juli august howev given gener season coronaviru infect drop summer
month increas winter may see spike earli fall
point estim put like number infect american first
infect wave million million given rel small percentag
immun strong enough protect futur outbreak herd immun need
infect although infect rate like declin summer month former fda
commission scott gottlieb de facto coronaviru czar continu stress need
embrac new normal instanc maintain social distanc allow busi
reopen state look move recreat activ religi servic even restaur
dine option outsid would maintain physic separ reduc surfac contact
individu combin environment factor heat humid could
regardless need vaccin remain high healthcar expert
agre take least two year develop success candid shorter-term
approach treat infect patient well prophylaxi protect high-risk individu
need discuss see promis short-term approach
convalesc plasma/hyperimmun ig antibodi therapi particular highlight
develop effort regeneron fast-pac respons pandem
page
plasma
patient recov gener antibodi viru remain
blood provid addit level immun reinfect isol plasma
patient known convalesc plasma administ product current infect
patient could help boost patient abil fight viru addit plasma
processed/fraction produc concentr standard antibodi dose
known hyperimmun globulin h-ig
use convalesc plasma/h-ig treat emerg epidem mean new idea fact
approach use treatment sever acut respiratori syndrom sar
well viral infect coronaviru epidem particularli sar mer patient
treat day infect improv outcom faster hospit discharg
benefit also note serious ill patient though data
on-going pandem convalesc plasma evalu treatment
first studi sever ill patient china publish march
acknowledg number caveat data import
placebo control studi note five critic ill patient
mechan ventil time treatment three taken ventil within
week treatment two stabl condit day transfus
compani convalesc plasma/hyperimmun ig effort
cheng et al use convalesc plasma therapi sar patient hong kong eur clin microbiol
yeh et al experi use convalesc plasma sever acut respiratori syndrom among
healthcar worker taiwan hospit antimicrob chemoth
ko et al challeng convalesc plasma infus therapi middl east respiratori coronaviru
et al treatment critic ill patient convalesc plasma jama
page
expect addit studi explor effect convalesc plasma/h-ig treatment
continu publish studi current list ct gov especi
recent issu guidanc fda link number compani develop
convalesc plasma/h-ig treatment option exhibit current on-going clinic studi
conduct medic center individu ind
although convalesc plasma transfus h-ig promis short-term passiv
immun number drawback challeng approach
patient identif order obtain product there high need effici
identifi recov patient order build donor databas given
shortag test throughout first infect wave combin
lack quick implement serolog test determin who
infect effici identifi potenti donor remain on-going challeng
identifi success donor potenti donor identifi antibodi
titer must analyz current fda recommend plasma individu
high antibodi titer use order effect drive neutral
effect need high antibodi plasma reduc potenti donor base
uniform product although donor may high titer antibodi sars-
antibodi repertoir wide variabl donor lead potenti
variat recipi respons
time-frame donor immun still question unclear long immun last
previous infect patient expert estim like year
reduc donor pool time requir new patient infect recov
viru order produc addit plasma product
capac limit donor treatment scheme ineffici plasma collect
distribut remain physic limit capac addit convalesc plasma
collect one donor effici treat one two recipi
given convalesc plasma/h-ig present compel near-term approach
treatment reliabl sustain approach need one approach
gener antibodi therapi provid compel solut problem
page
antibodi
complex infect
experi help
antibodi design
ultim goal provid vaccin induc potent immun respons
particular infecti diseas determin quit rapidli anim model take
time ethic determin level protect effect human instead
rapidli develop treatment vaccin strategi use broken apart larg
quantiti antibodi target pathogen interest gener outsid human
bodi thu much like convalesc plasma/h-ig gener antibodi therapi
use protect neutral fight pathogen interest discuss approach
provid overview current antibodi therapi develop landscap
sinc identifi end research elucid structur
viru particular spike protein major surfac protein viru use enter infect
host understand three-dimension shape confirm chang
viru bind enter cell import design target approach treatment
howev fulli understand structur complic presenc glycan sugar
moieti cover spike protein help hide immun system said
scientist recent map glycan coat order help identifi area target
antibodi penetr bind spike protein
neutral viru research look way block function spike protein
order inhibit enter host cell one approach directli block bind
viru host receptor angiotensin convert enzym host receptor
use sar epidem addit spike protein requir
conform chang host membran fusion second approach design identifi
antibodi block abil protein undergo structur chang final
debat literatur viral-depend enzym break open
enter host cell proteas furin trypsin etc target cleavag site spike
protein present third bind option neutral antibodi
model structure-funct relationship spike protein help design
antibodi approach anoth use tool explor antibodi repertoir
patient recov infect mani biopharma compani
use strategi identifi natur occur neutral antibodi screen vast
librari candid determin best therapeut candid candid
identifi scale-up product begin number manufactur process use
 clone antibodi sequenc high produc cell line product fuse immun cell
hybridoma cell produc immort produc cell line
exhibit highlight compani current develop antibodi
therapi compani use neutral antibodi isol recov covid-
patient help design potenti therapi note regeneron astrazeneca
cover util addit approach antibodi develop includ human
mous model ultim speed develop timelin regeneron expect enter
clinic late-jun antibodi cocktail player far behind
addit highlight on-going work biotech cover disclos
develop extend half-lif antibodi therapi could lengthen time-frame dose
wrapp et al cryo-em structur spike prefus conform scienc
watanab et al site-specif analysi glycan shield biorxiv
page
howev program still preclin develop
unclear point success candid move clinic
page
drill
regn effort
announc mid-march would pursu two approach treat
evalu kevzara treat critic ill patient experienc acut
respiratori distress syndrom ard develop antibodi cocktail
prophylact early/late-stag treatment patient
first approach repurpos kevzara sarilumab antibodi treat
sever patient experienc ard condit brought inflamm
massiv inflamm white blood cell lung placebo-control adapt
studi began enrol patient march top-lin data recent releas
portion studi data messi sever patient oxygen supplement
without mechan high-flow oxygen show neg trend kevzara vs placebo
though reproduc portion studi critic patient high-flow
oxygen mechan ventil icu high-dos cohort show benefit
number clinic outcom exhibit plan continu enrol critic patient
high-dos cohort data readout expect june
second approach describ detail use antibodi cocktail target
taken two parallel approach develop potent neutral antibodi
use velocimmun platform human mous model combin insight
convalesc plasma isol recov patient
page
approach treat
given effect vaccin wide avail next month shorter-term
treatment approach pandem greatli need treat infect
individu well prophylact strategi protect high-risk develop
diseas healthcar worker nurs home regn antibodi cocktail approach
allow target potent neutral antibodi identifi manufactur ex vivo outsid
bodi deliv patient passiv vaccin approach temporari
compani stranger treat infecti diseas approach previou
experi design treatment rsv mer ebola although note regn
rsv antibodi effort pan suptavumab singl antibodi rsv meet
primari endpoint studi ebola program use antibodi cocktail
success clinic specif ebola compani use velocimmun platform
produc cocktail three fully-human antibodi viru phase data
palm trial publish new england journal medicin decemb
demonstr surviv rate administ earlier cours diseas vs
zmapp control arm overal saw patient aliv day compar
treat compel data result studi stop earli
april fda accept bla review target action date octob
disclos mid-march recov thousand antibodi
genet human mice well human survivor isol
antibodi subject high throughput screen determin best candid
block neutral effect compani lead candid scale-up
process human trial track start june bar scale-up delay
cocktail treatment consist two human antibodi bind
block viruss spike protein help ensur target coverag even mutat region
aris mutat rate on-going topic concern especi develop
long-term vaccin co-found cso georg yancopoulo note interview stat
news abl gener vast major spike mutant variant alreadi
identifi cocktail remain effect howev question still linger
effect select pressur neutral antibodi mutat abil
spike protein biolog point entir predict
manag indic work toward goal produc hundr
thousand prophylact dose antibodi cocktail per month expect end
summer smaller batch avail initi clinic test begin summer
june wherein compani expect begin test treatment three set prophylact
earli infect intervent late infect intervent would expect fairli quick read
trial run patient late-stag diseas would expect longer follow-up time-frame
prophylaxi earli intervent set
point difficult know certainti exact commerci opportun regn
antibodi cocktail think tamiflu oseltamivir phosphat provid one comp
antibodi therapi success produc abl manufactur exact approv
pathway/timing/set unclear expect initi stockpil occur would
mulangu et al random control trial ebola viru diseas therapeut nejm
page
still lot unpack
join us
discuss
may
maintain time assum on-going wave outbreak scenario think
would reason expect annual sale tamiflu rang given
regn antibodi cocktail biolog reason believ number could higher
howev acknowledg regn commentari articul pursuit
antibodi cocktail profit-driven endeavor combin number
import unknown potenti differ dose level requir treatment vs
prophylact use prophylact dose frequenc price util
vaccin produc like util mild moder affect patient believ bit
earli know exact valu
like regn approach develop therapi understand
treatment landscap rapidli evolv day-to-day gain better understand regn
approach join us sit co-found cso georg yancopoulo may
discuss compani uniqu develop capabl call email us registr
instruct topic discuss includ
view util antibodi wake mix data recent sever
updat compani antibodi cocktail approach expect news flow therapeut
numer topic high interest includ vaccin timelin util practic
convalesc plasma well broader topic
page
revamp model new account present
recal last year regeneron partner sanofi disclos plan restructur antibodi
agreement recent final went effect april
restructur agreement sole respons praluent us record
us net product sale sanofi sole respons ex-u pay royalti
net product sale leav end-us praluent revenu estim unchang
incorpor restructur model describ
addit announc effect januari account present
collabor agreement sanofi bayer teva other modifi
reimburs sg expens longer recogn total revenu net
within respect expens line similarli up-front mileston payment longer
includ part total revenu rather recogn contra-expens new
oper incom expens line incom statement net neutral ep essenti
revenu expens decreas equal amount oper incom line item
unchang regn new report structur shown
new structur report
us praluent includ net product sale effect april
provid detail account chang slide deck investor faq document
includ histor reconcili old account present new one
includ quarterli result painstakingli incorpor
histor reconcili model updat estim use
new present walk account adjust alon net
neutral ep instanc total revenu oper expens estim
lower new account present compar old account
present ep estim unchang line regn
guidanc total revenu oper expens lower new
account present prior account treatment howev clariti certain
expens item exampl disclos sanofi reimburs collabor
manufactur larg offset cocm expens modifi expens estim
along praluent restructur modestli accret ep
estim higher prior estim low-singl digit percentag rang
page
present
view chang account present need make report
top-lin figur repres net product sale collabor profit compani
without skew higher expens reimburs gross-up somewhat black
box difficult forecast exampl new present sanofi collabor revenu
simplifi includ regn share collabor profit reimburs
manufactur commerci suppli understand larg off-set cocm
expens expens reimburs compon sanofi collabor revenu
net expens line regn incom statement anyway
reimburs commercialization-rel expens reimburs expens
longer includ sanofi collabor revenu
perspect look regn surpris histori variou compon revenu
show two exhibit magnitud beats/miss collabor
revenu gener higher magnitud beats/miss us eylea
largest compon product revenu signific top-lin beat miss often
driven collabor us eylea larg think black box
compon collaborative/oth revenu simplifi account present
hope make forecast regn top-lin expens item straightforward
revenu earn surpris histori
note revenu item highlight green red magnitud beat miss exceed given quarter non-gaap ep highlight green red ep beat
miss given quarter
condens revenu earn surpris histori
note revenu beat miss highlight green red magnitud exceed given quarter non-gaap ep highlight
green red ep beat miss given quarter
page
best
incorpor new
present
histor result
incorpor histor reconcili provid shown exhibit
get better handl forward estim chang new account
present note revenu expens adjust exactli off-set note also
also provid quarterli reconcili also incorpor
model show
chart show prior estim old account method also show
updat estim old new account present note ep
estim come slightli result new account present
rather reflect impact praluent restructur also refin
expens estim
instanc recent began break one compon sanofi collabor
revenu reimburs manufactur commerci suppli previous lump
revenu sanofi antibodi collabor recur
expens reimburs larg offset cocm expens previou model littl
clariti revenu line assum declin significantli howev
manufactur reimburs broken incorpor model
see drive posit ep adjust
page
prior current estim old new account present
page
changesu praluent revenu recogn start prior current revenuepsc prior psc current sanofi collabor revenuepsc prior old psc current old account psc current new bayer collabor revenuepsc prior old psc current old account psc current new revenuepsc prior old psc current old account psc current new total revenuepsc prior old psc current old account psc current new expensescocmpsc prior psc current old account psc current new expensepsc prior psc current old account psc current new sg expensepsc prior psc current old account psc current new oper incom expensepsc prior psc current old account account psc current new total opexpsc prior psc current old account psc current new ep net impact account adjust non-gaap epspsc prior current exhibit
increas target
note compon shown red previous includ antibodi revenu exclud new account present
compon shown green previous includ antibodi revenu still includ new account present
estim adjust expect clariti report ep
stay consist valuat methodolog appli multipl ep
target increas partial laps valuat period higher ep
page
good sold
product sale
collabor manufactur
collabor revenu
total revenu
sell gener administr
total revenu
statement oper
dollar except per share data
provis incom tax tax benefit
note chang account present colalbor effect estim reflect new account present effect
current disclosur inform compani locat http //www pipersandl com/researchdisclosur
